相似文献
1
Adjunctive use of platelet glycoprotein IIb/IIIa inhibitors for carotid angioplasty and stent placement: time to say good bye?
J Endovasc Ther. 2003 Feb;10(1):42-4. doi: 10.1177/152660280301000109.
2
Evaluation of glycoprotein IIb/IIIa inhibitors in carotid angioplasty and stenting.
J Endovasc Ther. 2003 Feb;10(1):33-41. doi: 10.1177/152660280301000108.
3
4
Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors.
Chest. 2005 Feb;127(2 Suppl):53S-59S. doi: 10.1378/chest.127.2_suppl.53S.
5
[Clinical use of glycoprotein IIb/IIIa inhibitors].
Ann Ital Med Int. 1998 Jul-Sep;13(3):163-8.
6
Abciximab, eptifibatide, and tirofiban: comparison of parenteral glycoprotein IIb/IIIa inhibitors.
Conn Med. 1999 Aug;63(8):483-7.
7
A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.
Circ Cardiovasc Interv. 2009 Jun;2(3):230-6. doi: 10.1161/CIRCINTERVENTIONS.108.847996. Epub 2009 Apr 21.
8
Evaluation of bleeding complications associated with glycoprotein IIb/IIIa inhibitors.
Ann Pharmacother. 2004 Nov;38(11):1783-8. doi: 10.1345/aph.1E048. Epub 2004 Sep 21.
9
Transvenous pacing causing tamponade in patients receiving glycoprotein IIb/IIIa inhibitors for percutaneous coronary intervention.
J Invasive Cardiol. 2007 Feb;19(2):E40-2.
10
A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
Catheter Cardiovasc Interv. 2011 Jun 1;77(7):1001-9. doi: 10.1002/ccd.22876. Epub 2011 Jan 11.
Zotero 插件